Free Trial

Evotec (EVO) Competitors

Evotec logo
$4.34 +0.12 (+2.84%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$4.43 +0.09 (+2.07%)
As of 04:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EVO vs. TGTX, NUVL, LNTH, TLX, AXSM, AKRO, ADMA, PCVX, KRYS, and RYTM

Should you be buying Evotec stock or one of its competitors? The main competitors of Evotec include TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Vaxcyte (PCVX), Krystal Biotech (KRYS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

Evotec vs. Its Competitors

TG Therapeutics (NASDAQ:TGTX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

TG Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.

In the previous week, TG Therapeutics had 8 more articles in the media than Evotec. MarketBeat recorded 9 mentions for TG Therapeutics and 1 mentions for Evotec. Evotec's average media sentiment score of 1.02 beat TG Therapeutics' score of 0.83 indicating that Evotec is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TG Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Evotec
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TG Therapeutics presently has a consensus price target of $40.80, suggesting a potential upside of 12.43%. Evotec has a consensus price target of $5.93, suggesting a potential upside of 36.71%. Given Evotec's higher possible upside, analysts plainly believe Evotec is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Evotec
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

TG Therapeutics has higher earnings, but lower revenue than Evotec.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$329M17.51$23.38M$0.24151.21
Evotec$862.40M1.79-$212.18MN/AN/A

TG Therapeutics has a net margin of 10.13% compared to Evotec's net margin of -26.34%. TG Therapeutics' return on equity of 18.88% beat Evotec's return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics10.13% 18.88% 7.05%
Evotec -26.34%-21.51%-10.54%

Summary

TG Therapeutics beats Evotec on 11 of the 14 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVO vs. The Competition

MetricEvotecMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.50B$2.42B$5.54B$8.87B
Dividend YieldN/A1.77%5.39%4.10%
P/E RatioN/A8.8326.1719.90
Price / Sales1.79663.86413.55113.66
Price / CashN/A151.5836.1356.90
Price / Book1.494.548.025.38
Net Income-$212.18M$31.16M$3.15B$248.50M
7 Day Performance2.84%0.07%1.48%2.06%
1 Month Performance7.69%7.24%3.66%4.86%
1 Year Performance-15.73%1.37%34.68%20.24%

Evotec Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVO
Evotec
1.6537 of 5 stars
$4.34
+2.8%
$5.93
+36.7%
-12.3%$1.50B$862.40M0.004,827Positive News
TGTX
TG Therapeutics
3.7706 of 5 stars
$35.99
-2.0%
$40.80
+13.4%
+98.2%$5.83B$329M149.96290
NUVL
Nuvalent
3.736 of 5 stars
$76.30
-4.2%
$119.60
+56.7%
+10.3%$5.72BN/A-17.3840Analyst Upgrade
Insider Trade
LNTH
Lantheus
4.4515 of 5 stars
$81.86
+0.5%
$130.50
+59.4%
+1.4%$5.64B$1.53B23.26700Positive News
TLX
Telix Pharmaceuticals
N/A$16.07
+0.4%
$22.00
+36.9%
N/A$5.41B$516.72M0.00N/AGap Down
AXSM
Axsome Therapeutics
4.6788 of 5 stars
$104.39
+1.0%
$172.33
+65.1%
+31.6%$5.09B$385.69M-18.09380Analyst Revision
AKRO
Akero Therapeutics
3.6296 of 5 stars
$53.36
-5.0%
$82.50
+54.6%
+131.8%$4.48BN/A-27.3630
ADMA
ADMA Biologics
4.1061 of 5 stars
$18.21
+0.3%
$27.67
+51.9%
+59.1%$4.34B$426.45M21.42530
PCVX
Vaxcyte
1.8037 of 5 stars
$32.51
-0.2%
$136.50
+319.9%
-56.3%$4.20BN/A-8.15160News Coverage
Positive News
KRYS
Krystal Biotech
4.5544 of 5 stars
$137.46
-1.0%
$211.13
+53.6%
-20.4%$4.01B$290.52M33.04210News Coverage
Analyst Revision
RYTM
Rhythm Pharmaceuticals
3.7995 of 5 stars
$63.19
+0.7%
$77.31
+22.3%
+58.1%$3.99B$130.13M-22.49140

Related Companies and Tools


This page (NASDAQ:EVO) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners